FDA Approves BioCryst's Hereditary Angioedema Drug - Japan & Europe Next?

RTT News

by Super Admin 70 Views

The FDA has approved BioCryst Pharmaceuticals Inc.'s (BCRX) oral, once-daily ORLADEYO (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older.

Comments